|
| Species | Tumor | Model | Immunologic effect | References |
|
| Human | CRC () | | Gangliosides (GM2, GD1a, GT1b; serum)↑ | [116] |
| | | Antiganglioside antibodies (serum)↑ | |
| HCC () | | CD4+CD25+Foxp3+ cells (blood, ablation | [105] |
| | | zone surrounding tissue)↓ | |
| Prostate () | | IFNγ↑, TNF (serum)↑ | [85] |
| | | Tumor-specific T-cell responses (blood)↑ | |
| Prostate () | ± GM-CSF | Tumor-specific T-cell responses (blood)↑ | [85] |
| RCC () | + GM-CSF | Tumor-specific T-cell responses (blood)↑ | [87] |
| | | Tumor-specific antibodies (serum)↑ | |
| Liver metastases | | IL-6, TNF (serum)↑ | [84] |
| () | | Th1/Th2 ratio (blood)↑ | |
| CCC () | | | |
|
| Mouse (BALB/c) | CRC | Colon-26 ± krestin | CD8+ antitumor T-cell reactivity (spleen) | [94] |
| | | (↑) | |
| | | Number of metastases↓ | |
| | Colon-26 ± Treg | Tumor-specific CD8+ T cells (spleen)↑ | [96] |
| | depletion ± DC + BCG | Tumor growth (distant tumors)↓ | |
| | Colon-26 ± | Tumor-specific T cells (spleen, draining | [97] |
| | cyclophosphamide | lymph nodes)↑ | |
| | | Tumor growth (rechallenge)↓ | |
| Mammary | MT-901 | IFNγ, IL-12 (serum)↑ | [83] |
| | | Tumor-specific T cells (draining | |
| | | lymph nodes but not in spleen)↑ | |
| | | NK cell activity (spleen)↑ | |
| | | Tumor growth (rechallenge)↓ | |
| | | T cells (draining lymph nodes)↑ | [95] |
| | | Tumor-specific T cells (draining lymph | |
| | | nodes)↑ | |
| | | Pulmonary metastases↓ | |
| | | Tumor-specific T cells (draining lymph | [79] |
| | | nodes)↑ | |
| | | Pulmonary metastases (high-intensity | |
| | | freezing)↓ | |
| | | Pulmonary metastases (low-intensity | |
| | | freezing)↑ | |
| Melanoma | B16-OVA ± imiquimod | Tumor-specific T cell proliferation↑ | [98] |
| | | Tumor growth (rechallenge)↓ | |
| | B16-MO5 ± DC | Tumor growth (rechallenge)↓ | [92] |
|
| Mouse (C57BL/6) | Melanoma | B16-OVA ± | DC maturation and antigen uptake | [69] |
| | CTLA4-mAb | (TDLN)↑ | |
| | | Tumor growth (rechallenge)↓ | |
| | B16-OVA ± CpG | DC (TDLN)↑ | [135] |
| | | CD4+, CD8+ T cells (TDLN)↑ | |
| | | OVA-specific T cells (TDLN)↑ | |
| | | Tumor growth (rechallenge after | |
| | | peritumoral CpG administration)↓ | |
|
| Mouse (NIH | Melanoma | IIB-MEL-J (human) | Neutrophils (RB6-5CG+) | [86] |
| (S)-nu) | | ± GM-CSF | (tumor-surrounding tissue)↑ | |
| | | macrophages (F4/80+; tumor-surrounding tissue)↑ | |
| | | DC (DEC205+; tumor-surrounding | |
| | | tissue)↑ | |
|
| Mouse (OT-I T cell | Lung | Lewis lung tumor | Tumor-specific CD8+ T-cell | [92] |
| receptor (Vα2/Vβ5) | | D122 ± DC | proliferation↑ | |
| transgenic) | | | Th1 responses↑ | |
| | | Tumor growth (lung metastases)↓ | |
|
| Rat (Wistar) | Glioma | C6 | CD3+ and CD4+ T-cell percentages (blood)↑ | [89] |
| | | CD4+/CD8+ ratio (blood)↑ | |
|
